Predictors of Prostate Volume Reduction Following Neoadjuvant Cytoreductive Androgen Suppression

Overview

Journal J Contemp Brachytherapy

Date 2016 Nov 30

PMID 27895677

Citations 3

Authors

Krishan R Jethwa

Keith M Furutani

Lance A Mynderse

Torrence M Wilson

Richard Choo

Bernard F King

Eric Bergstralh

Brian J Davis

Affiliations

Soon will be listed here.

Abstract

Purpose: Limited duration cytoreductive neoadjuvant hormonal therapy (NHT) is used prior to definitive radiotherapeutic management of prostate cancer to decrease prostate volume. The purpose of this study is to examine the effect of NHT on prostate volume before permanent prostate brachytherapy (PPB), and determine associated predictive factors.

Material And Methods: Between June 1998 and April 2012, a total of 1,110 patients underwent PPB and 207 patients underwent NHT. Of these, 189 (91.3%) underwent detailed planimetric transrectal ultrasound before and after NHT prior to PPB. Regression analysis was used to assess predictors of absolute and percentage change in prostate volume after NHT.

Results: The median duration of NHT was 4.9 months with inter quartile range (IQR), 4.2-6.6 months. Prostate-specific antigen (PSA) reduced by a median of 97% following NHT. The mean prostate volume before NHT was 62.5 ± 22.1 cm (IQR: 46-76 cm), and after NHT, it was 37.0 ± 14.5 cm (IQR: 29-47 cm). The mean prostate volume reduction was 23.4 cm (35.9%). Absolute prostate volume reduction was positively correlated with initial volume and inversely correlated with T-stage, Gleason score, and NCCN risk group. In multivariate regression analyses, initial prostate volume ( < 0.001) remained as a significant predictor of absolute and percent prostate volume reduction. Total androgen suppression was associated with greater percent prostate volume reduction than luteinizing hormone releasing hormone agonist (LHRHa) alone ( = 0.001).

Conclusions: Prostate volume decreased by approximately one third after 4.9 months of NHT, with total androgen suppression found to be more efficacious in maximizing cytoreduction than LHRHa alone. Initial prostate volume is the greatest predictor for prostate volume reduction.

Citing Articles

XModNN: Explainable Modular Neural Network to Identify Clinical Parameters and Disease Biomarkers in Transcriptomic Datasets.

Oldenburg J, Wagner J, Troschke-Meurer S, Plietz J, Kaderali L, Volzke H Biomolecules. 2025; 14(12.

PMID: 39766207 PMC: 11673716. DOI: 10.3390/biom14121501.

The Role of Transurethral BPH Surgeries in Management of Urinary Symptoms in Prostate Cancer Patients, Narrative Review.

Elsaqa M, El Tayeb M Curr Urol Rep. 2024; 26(1):7.

PMID: 39352587 PMC: 11445351. DOI: 10.1007/s11934-024-01229-1.

Long-term oncological outcomes after multimodal treatment for locally advanced prostate cancer.

Roldan F, Falagario U, Olsson M, Salas R, Aly M, Egevad L BJUI Compass. 2024; 5(9):885-892.

PMID: 39323926 PMC: 11420104. DOI: 10.1002/bco2.414.

Alterations of Sexual and Erectile Functions after Brachytherapy for Prostate Cancer Based on Patient-Reported Questionnaires.

Gesztesi L, Kocsis Z, Jorgo K, Frohlich G, Polgar C, Agoston P Prostate Cancer. 2024; 2024:5729185.

PMID: 38312318 PMC: 10834089. DOI: 10.1155/2024/5729185.

References

Davis B, Horwitz E, Lee W, Crook J, Stock R, Merrick G . American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012; 11(1):6-19. DOI: 10.1016/j.brachy.2011.07.005. View

Samper P, Lopez Carrizosa M, Perez Casas A, Vallejo C, Carmen Rubio Rodriguez M, Perez Vara C . Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy. Clin Transl Oncol. 2006; 8(8):599-605. DOI: 10.1007/s12094-006-0066-0. View

Solhjem M, Davis B, Pisansky T, Wilson T, Mynderse L, Hillman D . Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J. 2005; 10(6):343-8. DOI: 10.1097/00130404-200411000-00003. View

Stone N, Stock R . Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control, and morbidity. Brachytherapy. 2013; 12(3):217-21. DOI: 10.1016/j.brachy.2012.10.002. View

DuBois D, Prestidge B, Hotchkiss L, Prete J, Bice Jr W . Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology. 1998; 207(3):785-9. DOI: 10.1148/radiology.207.3.9609905. View

Forman J, Kumar R, Haas G, Montie J, Porter A, Mesina C . Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest. 1995; 13(1):8-15. DOI: 10.3109/07357909509024889. View

Ebara S, Manabe D, Kobayashi Y, Tanimoto R, Saika T, Nasu Y . The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Med Okayama. 2008; 61(6):335-40. DOI: 10.18926/AMO/32878. View

Sanghani M, Schultz D, Tempany C, Titelbaum D, Renshaw A, Loffredo M . Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology. 2003; 62(3):487-91. DOI: 10.1016/s0090-4295(03)00463-1. View

Kang S, Chou R, Dodge R, Clough R, Kang H, Bowen M . Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys. 2001; 50(4):937-45. DOI: 10.1016/s0360-3016(01)01530-9. View

10.

Gleave M, Goldenberg S, Chin J, Warner J, Saad F, Klotz L . Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001; 166(2):500-6; discussion 506-7. View

11.

Whittington R, Broderick G, Arger P, Malkowicz S, EPPERSON R, Arjomandy B . The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1999; 44(5):1107-10. DOI: 10.1016/s0360-3016(99)00119-4. View

12.

Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M . Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys. 2002; 52(2):453-60. DOI: 10.1016/s0360-3016(01)02658-x. View

13.

Smith S, Wallner K, Merrick G, Butler W, Sutlief S, Grimm P . Interpretation of pre- versus postimplant TRUS images. Med Phys. 2003; 30(5):920-4. DOI: 10.1118/1.1568980. View

14.

Stone , Stock . Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer. Mol Urol. 2000; 3(3):239-244. View

15.

Speight J, Shinohara K, Pickett B, Weinberg V, Hsu I, Roach 3rd M . Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid. Int J Radiat Oncol Biol Phys. 2000; 48(5):1461-7. DOI: 10.1016/s0360-3016(00)00798-7. View

16.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L . Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60(1):15-23. DOI: 10.1016/j.ijrobp.2004.02.022. View

17.

Prestidge B, Prete J, Buchholz T, Friedland J, Stock R, Grimm P . A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys. 1998; 40(2):461-5. DOI: 10.1016/s0360-3016(97)00715-3. View

18.

Buyyounouski M, Davis B, Prestidge B, Shanahan T, Stock R, Grimm P . A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy. 2012; 11(4):299-305. DOI: 10.1016/j.brachy.2011.12.012. View

19.

Eri L, Thomassen H, Brennhovd B, Haheim L . Accuracy and repeatability of prostate volume measurements by transrectal ultrasound. Prostate Cancer Prostatic Dis. 2003; 5(4):273-8. DOI: 10.1038/sj.pcan.4500568. View

20.

Zelefsky M, Harrison A . Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997; 49(3A Suppl):38-45. DOI: 10.1016/s0090-4295(97)00168-4. View